A germline variant in the TP53 polyadenylation signal confers cancer susceptibility

Research output: Contribution to journalLetterResearchpeer-review

  • Simon N Stacey
  • Patrick Sulem
  • Aslaug Jonasdottir
  • Gisli Masson
  • Julius Gudmundsson
  • Daniel F Gudbjartsson
  • Olafur T Magnusson
  • Sigurjon A Gudjonsson
  • Bardur Sigurgeirsson
  • Kristin Thorisdottir
  • Rafn Ragnarsson
  • Kristrun R Benediktsdottir
  • Bjørn Andersen Nexø
  • Anne Tjønneland
  • Kim Overvad
  • Peter Rudnai
  • Eugene Gurzau
  • Kvetoslava Koppova
  • Kari Hemminki
  • Cristina Corredera
  • Victoria Fuentelsaz
  • Pilar Grasa
  • Sebastian Navarrete
  • Fernando Fuertes
  • Maria D García-Prats
  • Enrique Sanambrosio
  • Angeles Panadero
  • Ana De Juan
  • Almudena Garcia
  • Fernando Rivera
  • Dolores Planelles
  • Virtudes Soriano
  • Celia Requena
  • Katja K Aben
  • Michelle M van Rossum
  • Ruben G H M Cremers
  • Inge M van Oort
  • Dick-Johan van Spronsen
  • Jack A Schalken
  • Wilbert H M Peters
  • Brian T Helfand
  • Jenny L Donovan
  • Freddie C Hamdy
  • Daniel Badescu
  • Ovidiu Codreanu
  • Banasik, Karina
  • Torben Jørgensen
  • Daniel R Witte
  • Hansen, Torben
  • Pedersen, Oluf Borbye
  • Swedish Low-risk Colorectal Cancer Study Group
To identify new risk variants for cutaneous basal cell carcinoma, we performed a genome-wide association study of 16 million SNPs identified through whole-genome sequencing of 457 Icelanders. We imputed genotypes for 41,675 Illumina SNP chip-typed Icelanders and their relatives. In the discovery phase, the strongest signal came from rs78378222[C] (odds ratio (OR) = 2.36, P = 5.2 × 10(-17)), which has a frequency of 0.0192 in the Icelandic population. We then confirmed this association in non-Icelandic samples (OR = 1.75, P = 0.0060; overall OR = 2.16, P = 2.2 × 10(-20)). rs78378222 is in the 3' untranslated region of TP53 and changes the AATAAA polyadenylation signal to AATACA, resulting in impaired 3'-end processing of TP53 mRNA. Investigation of other tumor types identified associations of this SNP with prostate cancer (OR = 1.44, P = 2.4 × 10(-6)), glioma (OR = 2.35, P = 1.0 × 10(-5)) and colorectal adenoma (OR = 1.39, P = 1.6 × 10(-4)). However, we observed no effect for breast cancer, a common Li-Fraumeni syndrome tumor (OR = 1.06, P = 0.57, 95% confidence interval 0.88-1.27).
Original languageEnglish
JournalNature Genetics
Volume43
Issue number11
Pages (from-to)1098-1103
Number of pages6
ISSN1061-4036
DOIs
Publication statusPublished - 1 Jan 2011

ID: 35312725